<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568944</url>
  </required_header>
  <id_info>
    <org_study_id>R21DE020916</org_study_id>
    <secondary_id>Pro00000394</secondary_id>
    <secondary_id>R21DE020916</secondary_id>
    <nct_id>NCT01568944</nct_id>
  </id_info>
  <brief_title>Role of Infected Blood Dendritic Cells in Heart Disease Risk</brief_title>
  <official_title>Peripheral Blood Dendritic Cells and Periodontitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that blood dendritic cells harbor pathogens from the oral
      cavity in chronic periodontitis and disseminate these pathogens to atherosclerotic plaques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To address this hypothesis, a clinical study in humans with moderate to severe chronic
      periodontitis has been designed. This is an interventional study involving scaling and root
      planing and two arms: 1. treatment with PO amoxocillin/metronidazole plus chlorhexidine oral
      rinse; 2. no antibiotics or oral rinse. It is expected that the antibiotics plus
      chlorhexidine will prevent the dendritic cell response to infection (bacteremia) elicited by
      scaling and root planing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Blood Dendritic Cells From Baseline</measure>
    <time_frame>30 days</time_frame>
    <description>The frequency of blood dendritic cells, i.e. % CCR6+CD1a+ DCs by flow cytometry 30 days after treatment with 7 day regimen of antibiotics, mouthrinse therapy and scaling and root planing (SRP) will be compared to those who did not receive the antibiotics, but did receive mouthrinse and scaling and root planing (SRP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Probing Attachment Levels</measure>
    <time_frame>30 days</time_frame>
    <description>Probing attachment levels (distance from the cemento-enamel junction to the base of the periodontal pocket in mm at 6 sites p[er tooth) will be monitored after 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Cytokine Response</measure>
    <time_frame>30 days</time_frame>
    <description>serum CCL20 in pg/ml by ELISA will be measured after 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probing Depths</measure>
    <time_frame>30 days</time_frame>
    <description>Probing depths (distance from the free gingival margin to the base of the pocket in mm at six sites per tooth) will be monitored after 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plaque Index</measure>
    <time_frame>30 days</time_frame>
    <description>Plaque index of Silness and Loe will be monitored at buccal and lingual surfaces of all teeth after 30 days:
0 no visible microbial plaque
thin film of visible microbial plaque in sulcus
moderate accumulation of plaque in sulcus
large amount of plaque in sulcus or along free gingival margin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gingival Index</measure>
    <time_frame>30 days</time_frame>
    <description>Gingival index of Loe and Silness on facial, lingual and mesial surfaces of all teeth will be monitored after 30 days:
0 Normal, no inflammation
Mild inflammation, slight color change and edema, no bleeding
Moderate inflammation, redness, edema, bleeds on probing
Severe inflammation, marked redness and edema ulceration, spontaneous bleeding</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Chronic Periodontitis</condition>
  <arm_group>
    <arm_group_label>Oral Antibiotic and Oral Rinse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Antibiotic and Oral Rinse</intervention_name>
    <description>PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID</description>
    <arm_group_label>Oral Antibiotic and Oral Rinse</arm_group_label>
    <other_name>Peridex/Flagyl/Amoxil/lansoprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Treatment</intervention_name>
    <description>Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
    <arm_group_label>Oral Antibiotic and Oral Rinse</arm_group_label>
    <arm_group_label>Standard Treatment</arm_group_label>
    <other_name>Scaling</other_name>
    <other_name>Root planing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  generalized moderate to severe chronic periodontitis

        Exclusion Criteria:

          -  diabetes

          -  antibiotics treatment within 3 months

          -  treatment with steroids, phenytoin, cyclosporin, coumadin

          -  presence of conditions requiring prophylactic antibiotics per AHA

          -  cancer, HIV, hepB, lupus, prediagnosed heart disease, renal disease

          -  smoker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Cutler, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>GHSU-College of Dental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GHSU-CDM Clinical Research Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zeituni AE, McCaig W, Scisci E, Thanassi DG, Cutler CW. The native 67-kilodalton minor fimbria of Porphyromonas gingivalis is a novel glycoprotein with DC-SIGN-targeting motifs. J Bacteriol. 2010 Aug;192(16):4103-10. doi: 10.1128/JB.00275-10. Epub 2010 Jun 18.</citation>
    <PMID>20562309</PMID>
  </reference>
  <reference>
    <citation>Zeituni AE, Carrion J, Cutler CW. Porphyromonas gingivalis-dendritic cell interactions: consequences for coronary artery disease. J Oral Microbiol. 2010 Dec 21;2. doi: 10.3402/jom.v2i0.5782.</citation>
    <PMID>21523219</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <results_first_submitted>February 13, 2020</results_first_submitted>
  <results_first_submitted_qc>April 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2020</results_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Christopher Cutler</investigator_full_name>
    <investigator_title>Assoc. Dean Dental Medicine, Dept. Chair Periodontics</investigator_title>
  </responsible_party>
  <keyword>periodontal</keyword>
  <keyword>disease</keyword>
  <keyword>dendritic</keyword>
  <keyword>cells</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Chronic Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Antibiotic and Oral Rinse</title>
          <description>Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
Oral Antibiotic and Oral Rinse: PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
        </group>
        <group group_id="P2">
          <title>Standard Treatment</title>
          <description>Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Antibiotic and Oral Rinse</title>
          <description>Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
Oral Antibiotic and Oral Rinse: PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
        </group>
        <group group_id="B2">
          <title>Standard Treatment</title>
          <description>Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="4"/>
                    <measurement group_id="B2" value="48" spread="5"/>
                    <measurement group_id="B3" value="46" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Blood Dendritic Cells From Baseline</title>
        <description>The frequency of blood dendritic cells, i.e. % CCR6+CD1a+ DCs by flow cytometry 30 days after treatment with 7 day regimen of antibiotics, mouthrinse therapy and scaling and root planing (SRP) will be compared to those who did not receive the antibiotics, but did receive mouthrinse and scaling and root planing (SRP)</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Antibiotic and Oral Rinse</title>
            <description>Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
Oral Antibiotic and Oral Rinse: PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Blood Dendritic Cells From Baseline</title>
          <description>The frequency of blood dendritic cells, i.e. % CCR6+CD1a+ DCs by flow cytometry 30 days after treatment with 7 day regimen of antibiotics, mouthrinse therapy and scaling and root planing (SRP) will be compared to those who did not receive the antibiotics, but did receive mouthrinse and scaling and root planing (SRP)</description>
          <units>% MFI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="4"/>
                    <measurement group_id="O2" value="14" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Probing Attachment Levels</title>
        <description>Probing attachment levels (distance from the cemento-enamel junction to the base of the periodontal pocket in mm at 6 sites p[er tooth) will be monitored after 30 days</description>
        <time_frame>30 days</time_frame>
        <population>The number of teeth</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Antibiotic and Oral Rinse</title>
            <description>Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
Oral Antibiotic and Oral Rinse: PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
          </group>
        </group_list>
        <measure>
          <title>Probing Attachment Levels</title>
          <description>Probing attachment levels (distance from the cemento-enamel junction to the base of the periodontal pocket in mm at 6 sites p[er tooth) will be monitored after 30 days</description>
          <population>The number of teeth</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>tooth sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>tooth sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="6"/>
                    <measurement group_id="O2" value="4.6" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Cytokine Response</title>
        <description>serum CCL20 in pg/ml by ELISA will be measured after 30 days</description>
        <time_frame>30 days</time_frame>
        <population>CCL20 in pg/ml of serum will be measured by ELISA</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Antibiotic and Oral Rinse</title>
            <description>Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
Oral Antibiotic and Oral Rinse: PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Cytokine Response</title>
          <description>serum CCL20 in pg/ml by ELISA will be measured after 30 days</description>
          <population>CCL20 in pg/ml of serum will be measured by ELISA</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="5"/>
                    <measurement group_id="O2" value="32" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Probing Depths</title>
        <description>Probing depths (distance from the free gingival margin to the base of the pocket in mm at six sites per tooth) will be monitored after 30 days</description>
        <time_frame>30 days</time_frame>
        <population>Probing depths in mm at 192 sites per patient</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Antibiotic and Oral Rinse</title>
            <description>Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
Oral Antibiotic and Oral Rinse: PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
          </group>
        </group_list>
        <measure>
          <title>Probing Depths</title>
          <description>Probing depths (distance from the free gingival margin to the base of the pocket in mm at six sites per tooth) will be monitored after 30 days</description>
          <population>Probing depths in mm at 192 sites per patient</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>sites per mouth</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sites per mouth</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="3"/>
                    <measurement group_id="O2" value="4.7" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plaque Index</title>
        <description>Plaque index of Silness and Loe will be monitored at buccal and lingual surfaces of all teeth after 30 days:
0 no visible microbial plaque
thin film of visible microbial plaque in sulcus
moderate accumulation of plaque in sulcus
large amount of plaque in sulcus or along free gingival margin</description>
        <time_frame>30 days</time_frame>
        <population>plaque index at 64 sites per mouth will be measured</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Antibiotic and Oral Rinse</title>
            <description>Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
Oral Antibiotic and Oral Rinse: PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
          </group>
        </group_list>
        <measure>
          <title>Plaque Index</title>
          <description>Plaque index of Silness and Loe will be monitored at buccal and lingual surfaces of all teeth after 30 days:
0 no visible microbial plaque
thin film of visible microbial plaque in sulcus
moderate accumulation of plaque in sulcus
large amount of plaque in sulcus or along free gingival margin</description>
          <population>plaque index at 64 sites per mouth will be measured</population>
          <units>pI index</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <units_analyzed>sites per mouth</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sites per mouth</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gingival Index</title>
        <description>Gingival index of Loe and Silness on facial, lingual and mesial surfaces of all teeth will be monitored after 30 days:
0 Normal, no inflammation
Mild inflammation, slight color change and edema, no bleeding
Moderate inflammation, redness, edema, bleeds on probing
Severe inflammation, marked redness and edema ulceration, spontaneous bleeding</description>
        <time_frame>30 days</time_frame>
        <population>gingival index at 3 sites per tooth</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Antibiotic and Oral Rinse</title>
            <description>Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
Oral Antibiotic and Oral Rinse: PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
          </group>
          <group group_id="O2">
            <title>Standard Treatment</title>
            <description>Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
          </group>
        </group_list>
        <measure>
          <title>Gingival Index</title>
          <description>Gingival index of Loe and Silness on facial, lingual and mesial surfaces of all teeth will be monitored after 30 days:
0 Normal, no inflammation
Mild inflammation, slight color change and edema, no bleeding
Moderate inflammation, redness, edema, bleeds on probing
Severe inflammation, marked redness and edema ulceration, spontaneous bleeding</description>
          <population>gingival index at 3 sites per tooth</population>
          <units>GI</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <units_analyzed>3 sites per tooth</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>3 sites per tooth</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <desc>The antibiotic protocol is reported to induce gastric upset, diarrhea and/or vaginal candidiasis in some subjects. All subjects were asked if they had any of these symptoms and none were reported</desc>
      <group_list>
        <group group_id="E1">
          <title>Oral Antibiotic and Oral Rinse</title>
          <description>Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
Oral Antibiotic and Oral Rinse: PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
        </group>
        <group group_id="E2">
          <title>Standard Treatment</title>
          <description>Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
Standard Treatment: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>chairman</name_or_title>
      <organization>Dental College of Georgia</organization>
      <phone>706-7212442</phone>
      <email>chcutler@augusta.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

